×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SMMT – summit therapeutics inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SMMT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/26
08:01 am
smmt
Summit Therapeutics Inc. (NASDAQ: SMMT) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating. They now have a $35.00 price target on the stock, up previously from $23.00.
Medium
Report
Summit Therapeutics Inc. (NASDAQ: SMMT) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating. They now have a $35.00 price target on the stock, up previously from $23.00.
3/23
08:50 am
smmt
Is Summit Therapeutics a Millionaire Maker? [Yahoo! Finance]
Medium
Report
Is Summit Therapeutics a Millionaire Maker? [Yahoo! Finance]
3/21
04:15 pm
smmt
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/21
08:15 am
smmt
Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Low
Report
Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
3/21
08:15 am
smmt
Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Low
Report
Summit Therapeutics Inc. (NASDAQ: SMMT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
3/17
04:38 pm
smmt
Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer [Yahoo! Finance]
Low
Report
Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer [Yahoo! Finance]
3/17
04:24 pm
smmt
Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer
Low
Report
Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer
3/14
04:15 pm
smmt
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/24
06:54 am
smmt
Form 10-K Summit Therapeutics Inc. For: Dec 31
High
Report
Form 10-K Summit Therapeutics Inc. For: Dec 31
2/24
06:09 am
smmt
Form 8-K Summit Therapeutics Inc. For: Feb 24
High
Report
Form 8-K Summit Therapeutics Inc. For: Feb 24
1/24
04:24 pm
smmt
Form 8-K Summit Therapeutics Inc. For: Jan 22
Low
Report
Form 8-K Summit Therapeutics Inc. For: Jan 22
1/14
04:06 pm
smmt
Form 4 Summit Therapeutics Inc. For: Jan 12 Filed by: Anand Bhaskar
Medium
Report
Form 4 Summit Therapeutics Inc. For: Jan 12 Filed by: Anand Bhaskar
1/13
08:38 am
smmt
Form 8-K Summit Therapeutics Inc. For: Jan 13
Low
Report
Form 8-K Summit Therapeutics Inc. For: Jan 13
1/6
07:49 pm
smmt
Form 4 Summit Therapeutics Inc. For: Jan 02 Filed by: DUGGAN ROBERT W
Medium
Report
Form 4 Summit Therapeutics Inc. For: Jan 02 Filed by: DUGGAN ROBERT W
1/6
07:40 pm
smmt
Form 4 Summit Therapeutics Inc. For: Jan 02 Filed by: Zanganeh Mahkam
Medium
Report
Form 4 Summit Therapeutics Inc. For: Jan 02 Filed by: Zanganeh Mahkam
1/6
07:31 pm
smmt
Form 4 Summit Therapeutics Inc. For: Jan 02 Filed by: Huber Jeff
Medium
Report
Form 4 Summit Therapeutics Inc. For: Jan 02 Filed by: Huber Jeff
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/14
Summit Appoints Robert W. Duggan as Chief Executive Officer
27.7%
3/13 SUMMIT THERAPEU/S (NASDAQ: SMMT) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 22.3%
6/15 SUMMIT THERAPEU/S (NASDAQ: SMMT) was upgraded by analysts at TheStreet from a "d" rating to a "c-" rating. 13.3%
12/6 Form 6-K Summit Therapeutics plc For: Dec 06 10.8%
12/25 SUMMIT THERAPEU/S (NASDAQ: SMMT) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 8.3%
7/9 Summit’s DDS-04 Enterobacteriaceae Programme Demonstrates In Vivo Efficacy in Sepsis and Pneumonia 8.2%
3/25 SUMMIT THERAPEU/S (NASDAQ: SMMT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.25 price target on the stock. 7.8%
10/3 Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile Infection Compared to Standard of Care 6.1%
2/4 Summit Therapeutics to Present at the 2020 BIO CEO & Investor Conference 4.0%
12/6 Form 6-K/A Summit Therapeutics plc For: Dec 06 3.9%
3/13 SUMMIT THERAPEU/S (NASDAQ: SMMT) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 22.3%
6/15 SUMMIT THERAPEU/S (NASDAQ: SMMT) was upgraded by analysts at TheStreet from a "d" rating to a "c-" rating. 13.3%
12/6 Form 6-K Summit Therapeutics plc For: Dec 06 10.8%
12/25 SUMMIT THERAPEU/S (NASDAQ: SMMT) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 8.3%
7/9 Summit’s DDS-04 Enterobacteriaceae Programme Demonstrates In Vivo Efficacy in Sepsis and Pneumonia 8.2%
3/25 SUMMIT THERAPEU/S (NASDAQ: SMMT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.25 price target on the stock. 7.8%
10/3 Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile Infection Compared to Standard of Care 6.1%
2/4 Summit Therapeutics to Present at the 2020 BIO CEO & Investor Conference 4.0%
12/6 Form 6-K/A Summit Therapeutics plc For: Dec 06 3.9%
TOP News Decliners
5/1
SUMMIT THERAPEU/S (NASDAQ: SMMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
-12.0%
10/1 Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019 -10.7%
12/17 Form 6-K Summit Therapeutics plc For: Oct 31 -5.8%
10/11 Half-year report -5.7%
10/3 Summit Therapeutics up 17% premarket on positive ridinilazole data in CDI patients [Seeking Alpha] -5.5%
5/14 Form 6-K Summit Therapeutics plc For: May 14 -4.8%
11/8 SUMMIT THERAPEU/S (NASDAQ: SMMT) was downgraded by analysts at ValuEngine from a "sell" rating to a "strong sell" rating. -4.6%
1/27 Form 6-K Summit Therapeutics plc For: Jan 27 -3.9%
4/30 Summit Therapeutics Reports Financial Results for the Fourth Period and Eleven Months Ended December 31, 2019, and Operational Progress -3.8%
7/17 Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress -3.8%
10/1 Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019 -10.7%
12/17 Form 6-K Summit Therapeutics plc For: Oct 31 -5.8%
10/11 Half-year report -5.7%
10/3 Summit Therapeutics up 17% premarket on positive ridinilazole data in CDI patients [Seeking Alpha] -5.5%
5/14 Form 6-K Summit Therapeutics plc For: May 14 -4.8%
11/8 SUMMIT THERAPEU/S (NASDAQ: SMMT) was downgraded by analysts at ValuEngine from a "sell" rating to a "strong sell" rating. -4.6%
1/27 Form 6-K Summit Therapeutics plc For: Jan 27 -3.9%
4/30 Summit Therapeutics Reports Financial Results for the Fourth Period and Eleven Months Ended December 31, 2019, and Operational Progress -3.8%
7/17 Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress -3.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: